Hong Kong Herbal Biotech Stock Surges Despite No Revenue

Nasdaq‑listed biotech firm Regencell, specialising in traditional Chinese herbal treatments, has seen its stock soar by over 15,000 percent in 2025, lifting its valuation to roughly $9.7 billion despite having recorded no revenue in recent years, in a striking and unexplained market surge :contentReference[oaicite:4]{index=4}.